Related Experiment Videos
Evaluation of the safety of cantastim in normal humans
A Olinescu1, L D Radu, A Dolganiuc
1Cantacuzino Institute, Bucharest, Romania.
Abstract:
CANTASTIM, a good immunomodulatory agent obtained from a highly pathogenic strain of Pseudomonas aeruginosa was inoculated during 12 weeks in 21 healthy individuals aged 18-45 years. The subjects were clinically and laboratory investigated for body weight, antibodies against DNA, collage, cardiolipin, number of blood cells, blood and urine enzymes etc. After this intensive therapy, all the studied parameters were found in normal range of values. The results are a proof that this immunomodulator is not antigenic and has not side effects.
Insights
CANTASTIM, an immunomodulatory agent from Pseudomonas aeruginosa, was tested in 21 healthy adults. The study found no adverse effects, proving its safety and non-antigenic properties for therapeutic use.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Pseudomonas aeruginosa is a pathogen with potential for therapeutic agents.
- Immunomodulatory agents require rigorous safety and efficacy testing.
Purpose of the Study:
- To evaluate the safety and immunomodulatory effects of CANTASTIM.
- To assess the antigenic potential and side effects of CANTASTIM in humans.
Main Methods:
- CANTASTIM was administered to 21 healthy individuals aged 18-45 years over 12 weeks.
- Clinical and laboratory parameters including body weight, antibody levels, blood cell counts, and enzyme activity were monitored.
Main Results:
- All monitored clinical and laboratory parameters remained within normal ranges.
- No antigenic properties or adverse side effects were observed during the study period.
Conclusions:
- CANTASTIM is a safe immunomodulatory agent.
- CANTASTIM demonstrates a favorable safety profile with no observed side effects or antigenic response.